Integer vs TransMedics
ITGR and TMDX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ITGR and TMDX compare
Integer is the larger company, worth 1.4 times as much as TransMedics ($4.3B against $3.2B).
On earnings, TransMedics is cheaper: it trades at 25.0× trailing earnings, against 42.5× for Integer.
TransMedics grew revenue faster over the last twelve months (28.5% versus −0.31% for Integer).
TransMedics keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with 5.7% at Integer.
TransMedics scores higher on the StockData Score (15 against 8 for Integer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ITGR | TMDX |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $3.2B |
| Share price | $126.70 | $91.38 |
| Change, 1 year | 82.3% | −23.3% |
| Change, 5 years | 41.2% | 301% |
| Beta (5Y) | 0.78 | 1.34 |
| Employees | 11K | 898 |
| StockData Score | ||
| Total score | 8 | 15 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 42.5× | 25.0× (better) |
| P/S | 2.4× (better) | 4.4× |
| P/B | 2.5× (better) | 5.8× |
| EV/EBITDA | 19.0× (better) | 21.5× |
| P/FCF | 52.6× (better) | 70.9× |
| PEG | 3.21 | – |
| FCF yield | 1.9% (better) | 1.4% |
| Fair value | $102.86 | $129.52 |
| Margin of safety | −23.2% | 29.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −0.31% | 28.5% (better) |
| Revenue growth, 5Y average | 11.5% | 88.2% (better) |
| Net income growth (TTM) | 19.3% | 57.4% (better) |
| EPS growth (TTM) | 24.7% | 47.8% (better) |
| EPS growth, 5Y average | 4.4% | – |
| Profitability | ||
| Gross margin | 24.6% | 58.6% (better) |
| Operating margin | 8.2% | 11.9% (better) |
| Net margin | 5.7% | 19.9% (better) |
| FCF margin | 4.5% | 6.1% (better) |
| Return on equity | 6.0% | 31.9% (better) |
| Return on invested capital | 5.0% | 2622% (better) |
| Financial health | ||
| Debt / equity | 0.71 | 0.10 (better) |
| Net debt / EBITDA | 4.16 (better) | −3.45 |
| Interest coverage | 3.9× (better) | 3.5× |
| Current ratio | 3.98 | 4.53 (better) |
| Altman Z-score | 2.88 (better) | 2.84 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | 2.3% | – |
| Shareholder yield | 2.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 120% | 100% |
| Held by insiders | 15.1% | 3.9% |
| Insider net buying, 12 months | −$5.2M | −$4.2M (better) |
| Short interest, % of float | 11.9% | 26.6% |
Go deeper
- ITGR stock overview
- ITGR income statement
- ITGR valuation and score
- TMDX stock overview
- TMDX income statement
- TMDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.